What are the key takeaways from this Biotech Hangout episode?

Key insights include: **Follow-On Market Dynamics:** October-November 2025 saw nearly $9 billion in follow-on financings across two months, the largest activity in 18 months. However, December deals show weaker post-market performance with stocks selling off after announcements, indicating investor fatigue and desire to lock in 2025 gains before year-end rather than sustained momentum.; **FDA Operational Crisis:** FDA staffing dropped to 2016 levels with 4,000 employees (20% of agency) departed in 2025. DOGE fired the HR department with no new hires completed, only transfers. Training new staff typically requires one year hiring plus two to three years training, creating long-term review capacity constraints despite day-to-day operations continuing.; **MFN Pricing Risk:** White House plans to expand Most Favored Nation pricing deals beyond large pharma to blanket policy across all biotechs. While initial deals with major drugmakers lack enforcement teeth, applying these frameworks to small and midsize companies could create disproportionate harm compared to large pharma's ability to absorb legacy product pricing pressure.

What did Daphne Zohar and Bruce Booth discuss on Biotech Hangout?

Biotech Hangout's 2025 year-end review examines market recovery after years of underperformance, with XBI reaching 124. Discussion covers FDA staffing crisis with 4,000 employees lost, MFN pricing policy concerns, follow-on financing trends exceeding $9 billion in October-November, and predictions for 2026 IPO activity and continued M&A momentum. Key topics include: **Follow-On Market Dynamics:** October-November 2025 saw nearly $9 billion in follow-on financings across two months, the largest activity in 18 months. However, December deals show weaker post-market performance with stocks selling off after announcements, indicating investor fatigue and desire to lock in 2025 gains before year-end rather than sustained momentum.; **FDA Operational Crisis:** FDA staffing dropped to 2016 levels with 4,000 employees (20% of agency) departed in 2025. DOGE fired the HR department with no new hires completed, only transfers. Training new staff typically requires one year hiring plus two to three years training, creating long-term review capacity constraints despite day-to-day operations continuing..

How long is this episode of Biotech Hangout?

This episode is 58 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Biotech Hangout

Episode 167 - December 19, 2025

December 19, 2025

58 min episode · 2 min read

Daphne Zohar,Bruce Booth,Eric Schmidt

Episode

58 min

Read time

2 min

Topics

Career Growth, Health & Wellness, Investing

AI-Generated Summary

Published Feb 12, 2026

Key Takeaways

✓Follow-On Market Dynamics: October-November 2025 saw nearly $9 billion in follow-on financings across two months, the largest activity in 18 months. However, December deals show weaker post-market performance with stocks selling off after announcements, indicating investor fatigue and desire to lock in 2025 gains before year-end rather than sustained momentum.
✓FDA Operational Crisis: FDA staffing dropped to 2016 levels with 4,000 employees (20% of agency) departed in 2025. DOGE fired the HR department with no new hires completed, only transfers. Training new staff typically requires one year hiring plus two to three years training, creating long-term review capacity constraints despite day-to-day operations continuing.
✓MFN Pricing Risk: White House plans to expand Most Favored Nation pricing deals beyond large pharma to blanket policy across all biotechs. While initial deals with major drugmakers lack enforcement teeth, applying these frameworks to small and midsize companies could create disproportionate harm compared to large pharma's ability to absorb legacy product pricing pressure.
✓IPO Window Mechanics: Companies committing to IPO face four to five month timelines including legal work, SEC comments, and accounting requirements. With market sentiment improving post-Labor Day, expect 10-15 companies to flip from confidential to public S-1 filings in January 2026, though quality concerns exist about recycled 2024-2025 candidates with existing syndicates rushing to market first.
✓M&A as Ecosystem Function: Biotech M&A totaled nearly $240 billion in announced or closed deals by November 2025. Unlike tech, biotech lacks private growth capital providers at scale, making acquisitions by cash-rich pharma with existing distribution infrastructure the natural progression for delivering drugs to patients rather than building redundant commercial capabilities in overcapacity markets.

What It Covers

Biotech Hangout's 2025 year-end review examines market recovery after years of underperformance, with XBI reaching 124. Discussion covers FDA staffing crisis with 4,000 employees lost, MFN pricing policy concerns, follow-on financing trends exceeding $9 billion in October-November, and predictions for 2026 IPO activity and continued M&A momentum.

Key Questions Answered

•Follow-On Market Dynamics: October-November 2025 saw nearly $9 billion in follow-on financings across two months, the largest activity in 18 months. However, December deals show weaker post-market performance with stocks selling off after announcements, indicating investor fatigue and desire to lock in 2025 gains before year-end rather than sustained momentum.
•FDA Operational Crisis: FDA staffing dropped to 2016 levels with 4,000 employees (20% of agency) departed in 2025. DOGE fired the HR department with no new hires completed, only transfers. Training new staff typically requires one year hiring plus two to three years training, creating long-term review capacity constraints despite day-to-day operations continuing.
•MFN Pricing Risk: White House plans to expand Most Favored Nation pricing deals beyond large pharma to blanket policy across all biotechs. While initial deals with major drugmakers lack enforcement teeth, applying these frameworks to small and midsize companies could create disproportionate harm compared to large pharma's ability to absorb legacy product pricing pressure.
•IPO Window Mechanics: Companies committing to IPO face four to five month timelines including legal work, SEC comments, and accounting requirements. With market sentiment improving post-Labor Day, expect 10-15 companies to flip from confidential to public S-1 filings in January 2026, though quality concerns exist about recycled 2024-2025 candidates with existing syndicates rushing to market first.
•M&A as Ecosystem Function: Biotech M&A totaled nearly $240 billion in announced or closed deals by November 2025. Unlike tech, biotech lacks private growth capital providers at scale, making acquisitions by cash-rich pharma with existing distribution infrastructure the natural progression for delivering drugs to patients rather than building redundant commercial capabilities in overcapacity markets.

Notable Moment

The discussion revealed that Amicus Therapeutics, founded by John Crowley to treat his children's Pompe disease, was acquired by BioMarin for $4.8 billion after going public in May 2007 at $15 per share and selling for $14.50—despite market cap growing 13-15x, illustrating massive dilution required to build rare disease companies over two decades.

Know someone who'd find this useful?

Episode Transcript

You're listening to biotech hangout, a live and unedited weekly discussion of all the latest news in our industry with a group of biotech insiders. I'm Daphne Zohar, and my cohosts today are Bruce Booth and Eric Schmidt. For more information about our hosts and guest speakers or to listen to the most recent episode, please go to biotechhangout.com. So this is going to be our last Hangout episode this year, and it's a perfect time to review 2025 and put forth some thoughts regarding 2026 as well as touching on the latest news of the week. So starting with the markets, after underperforming for years, biotech rebounded in recent months, and reasons include macro rotations, biopharma as an AI trade hedge, and more importantly, fundamentals, including greater clarity on drug pricing, biotechs launching drugs successfully, and m and a momentum. Capital inflows are spiking, and we hear of a risk on environment. With that said, the IPO market has not yet fully opened, though follow on activity remains strong. Eric, you were saying the last few follow ons have been a bit more wobbly. Tell us more about that. Yeah. First, just a privilege to be on this last episode of the year with with you guys. I hope everyone has a safe and and happy holiday season and, get some some rest in. I mean, in terms of the market sentiment, Daphne, it just sort of feels to me that we're stumbling into year end a little bit. You know, maybe for the for the first time in the last three or four months now, biotech has modestly underperformed some of the broader indices. And some of the good news that we have had, we've seen some some initial pops in stock price performance, but a lot of these follow ons have come right on the heels of of such positive news flow and and maybe diluted out, the the post market deal performance, which has been mixed to to negative in some cases. We had this this week even a a couple of good announcements. So one from Immunome on their, Oh, boy. Their their their case inhibitor, and that was for Desmoid tumors, and stock was up relatively well and then sold off into and after the deal and another another transaction, from Kyverna. We may talk a little bit about this on their CD nineteen cell therapy for stiff versus disease, kind of the same reaction. Good first day of performance, deal comes, and a sell off. So at least from where I sit, it it seems like people just kinda wanna close the the books on 2025 and and go home. This is, as you guys know, the first year in which you could actually lock in some some positive stock gains, and the buy side just seems a little bit tired, a little bit, you know, kinda done with 2025. So, you know, hopefully, we we can sort of crawl into year end …

Get the full transcript (10,328 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Biotech Hangout transcripts →